XML 33 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Acquisitions
3 Months Ended
Mar. 31, 2019
Acquisitions [Abstract]  
Acquisitions
12.
Acquisitions

On January 22, 2018, the Company acquired the remaining 73% ownership in Innuvate Health Sciences, LLC (“Innuvate”), which owns a 92% interest in a nutritional product manufacturer. Prior to this acquisition, the Company owned 27% of Innuvate and accounted for it using the equity method. The remaining 8% ownership in the manufacturer will continue to be held by an unrelated third party. Under the terms of the agreement, the Company paid $23.5 million in cash and shares of the Company in exchange for the 73% ownership in Innuvate. Innuvate is a contract manufacturer that specializes in softgel and hardshell capsule manufacturing.

On February 12, 2018, the Company acquired the remaining 65% ownership in Treviso, LLC (“Treviso”), making Treviso a wholly owned subsidiary of the Company. Treviso is a personal care product manufacturer. Prior to this acquisition, the Company owned 35% of Treviso and accounted for it using the equity method. Under the terms of the purchase agreement, the Company has paid $83.9 million in cash and shares of the Company in exchange for the 65% ownership in Treviso. Treviso is a liquid contract manufacturing laboratory for premium personal care products.

On February 12, 2018, the Company acquired 100% ownership in L&W Holdings, Inc. (“L&W”) making L&W a wholly owned subsidiary of the Company. L&W is a packaging supplier company. Under the terms of the purchase agreement, the Company paid $25.0 million in shares of the Company in exchange for 100% ownership in L&W. L&W specializes in the distribution and packaging of products in the cosmetic and nutritional industries.

The following table summarizes the fair value of consideration transferred for the acquisitions disclosed above (in thousands):

  
Innuvate
  
Treviso
  
L&W Holdings
  
Total
 
             
Total cash consideration
 
$
17,587
  
$
14,648
  
$
  
$
32,235
 
Shares issued in conjunction with acquisition
  
5,863
   
69,252
   
25,000
   
100,115
 
Total consideration
 
$
23,450
  
$
83,900
  
$
25,000
   
132,350
 
Previously held equity interest in equity method Investments(1)
  
8,748
   
30,281
   
   
39,029
 
Total
 
$
32,198
  
$
114,181
  
$
25,000
  
$
171,379
 

(1)
The acquisitions of Innuvate and Treviso are considered step acquisitions, and accordingly, the Company remeasured its pre-existing 27% equity interest in Innuvate and 35% of Treviso immediately prior to completion of the acquisition to its estimated fair value of approximately $39.0 million. As a result of the remeasurement, the Company recorded a gain of approximately $13.6 million within other income (expense), during the first quarter of 2018, representing the excess of the approximate $39.0 million estimated fair value of its pre-existing 27% equity interest in Innuvate and 35% equity interest of Treviso over its transaction date carrying value of approximately $25.4 million.

The following table summarizes the fair value of the assets acquired for the acquisitions disclosed above (in thousands):

 
Innuvate
 
Treviso
 
L&W Holdings
 

 Life
 
Amount
 
Life
 
Amount
 
Life
 
Amount
 
             
Total current assets
  
$
6,219
   
$
19,659
   
$
7,353
 
Fixed assets
   
9,291
    
33,282
    
114
 
Customer list
9 years
  
5,100
 
9 years
  
16,500
 
7 years
  
6,500
 
Order backlog
5 months
  
200
 
10 months
  
4,700
 
4 months
  
900
 
Trademarks
7 years
  
900
 
6 years
  
1,300
 
5 years
  
600
 
Total current liabilities
   
(3,942
)
   
(3,740
)
   
(1,495
)
Other non-current liabilities
   
    
    
(1,731
)
Total identifiable net assets acquired
   
17,768
    
71,701
    
12,241
 
Goodwill
   
17,230
    
42,480
    
12,759
 
Fair value of noncontrolling interest
   
(2,800
)
   
    
 
Total consideration and value to be allocated to net assets
  
$
32,198
   
$
114,181
   
$
25,000
 

Pro forma and historical results of operations for the acquired companies have not been presented because they are not material, either individually or in the aggregate, to the company’s consolidated financial statements.